Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in untreated CLL with comorbidities
NCT02242942Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) (3 arms), sponsored by Roche. Primary endpoint: Progression-Free Survival at 3.75 years. Started Dec 2014; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02242942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242942.